Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Haakon Ragde"'
Autor:
Liv Cecilie Vestrheim Thomsen, Alfred Honoré, Lars Anders Rokne Reisæter, Bjarte Almås, Astrid Børretzen, Svein Inge Helle, Kristina Førde, Einar Klæboe Kristoffersen, Silje Helland Kaada, Guro Kristin Melve, Torjan Magne Haslerud, Martin Biermann, Iris Bigalke, Gunnar Kvalheim, Waqas Azeem, Jan Roger Olsen, Benjamin Gabriel, Stian Knappskog, Ole Johan Halvorsen, Lars Andreas Akslen, Duke Bahn, Klaus Pantel, Sabine Riethdorf, Haakon Ragde, Bjørn Tore Gjertsen, Anne Margrete Øyan, Karl-Henning Kalland, Christian Beisland
Publikováno v:
Cancer Immunology and Immunotherapy
Metastatic castration-resistant prostate cancer (mCRPC) is an immunologically cold disease with dismal outcomes. Cryoablation destroys cancer tissue, releases tumor-associated antigens and creates a pro-inflammatory microenvironment, while dendritic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa514300d3dcf5153ca8cadad17daf3a
https://hdl.handle.net/11250/3069109
https://hdl.handle.net/11250/3069109
Autor:
Alfred Honoré, Liv Cecilie Vestrheim Thomsen, Lars A. Akslen, Christian Beisland, Klaus Pantel, Bjørn Tore Gjertsen, Haakon Ragde, Svein Inge Helle, Einar Kleboe Kristoffersen, Ole J. Halvorsen, Duke Bahn, Lars A. R. Reisæter, Karl-Henning Kalland, Guro Kristin Melve, Sabine Riethdorf, Bjarte Almås, Martin Biermann, Anne Margrete Øyan, Kristina Førde, Waqas Azeem
Publikováno v:
Journal of Clinical Oncology. 38:3029-3029
3029 Background: Dendritic cell (DC)-based cryoimmunotherapy (CryoIT) was used to treat metastatic castration-resistant prostate cancer in a Phase I clinical trial. Primary objective was safety of treatment. Secondarily, clinical, radiological and im
Autor:
Jan Roger Olsen, Ole J. Halvorsen, Torjan Haslerud, Duke Bahn, Klaus Pantel, Anne Margrete Øyan, Jarle Rørvik, Martin Biermann, Liv Cecilie Vestrheim Thomsen, Lars A. R. Reisæter, Christian Beisland, Einar K. Kristoffersen, Haakon Ragde, Bjarte Almås, Gunnar Kvalheim, Svein Inge Helle, Karl-Henning Kalland, Alfred Honoré, Jannicke Frugård, Lars A. Akslen, Guro Kristin Melve, Waqas Azeem, Bjørn Tore Gjertsen, Sabine Riethdorf
Publikováno v:
Cancer Research. 78:CT066-CT066
Interim analysis data are presented for 13 patients with metastatic castration resistant prostate cancer treated with dendritic cell based cryoimmunotherapy (CryoIT) and at least three months follow-up (FU). In CryoIT autologous immature dendritic ce
Autor:
Alfred Honoré, Einar Kleboe Kristoffersen, Liv Cecilie Vestrheim Thomsen, Haakon Ragde, Christian Beisland, Guro Kristin Melve, Jannicke Frugård, Bjørn Tore Gjertsen, Torjan Haslerud, Anne Margrete Øyan, Lars A. R. Reisæter, Ole J. Halvorsen, Karl-Henning Kalland, Klaus Pantel, Bjarte Almås, Jarle Rørvik, Gunnar Kvalheim, Martin Biermann, Duke Bahn, Svein Inge Helle
Publikováno v:
Journal of Clinical Oncology. 36:e17014-e17014
e17014Background: Interim analysis data are presented for 13 pts with mCRPC treated with DC based CryoIT and at least 3 months follow-up (FU). CryoIT exposes tumor antigens in cryoablated tissue to...
Publikováno v:
Urology. 70:S36-S41
A growing number of studies have described an apparent synergy between systemic chemotherapy administration and the intratumoral injection of dendritic cells (DCs) in the successful treatment of murine tumors. A review of several of these studies is
Publikováno v:
Cancer. 89:135-141
BACKGROUND The purported lack of long term modern prostate brachytherapy outcome data continues to lead many physicians to recommend other, more traditional treatments. This concern for long term results has encouraged the authors to supplement their
Autor:
Haakon Ragde, Leroy J. Korb
Publikováno v:
Seminars in Surgical Oncology. 18:45-51
Prostate brachytherapy is an effective treatment option for clinically organ-confined prostate carcinoma. Observed 5- and 10-year follow-up have documented prostate-specific antigen (PSA) levels that were comparable to published radical prostatectomy
Autor:
Gerald P. Murphy, M. Rogers, S.J. Simmons, Benjamin A. Tjoa, Haakon Ragde, M.J. Troychak, G.M. Kenny, Alton L. Boynton, Abdel-Aziz A. Elgamal
Publikováno v:
The Prostate. 40:125-129
BACKGROUND A phase II trial, involving infusions of autologous dendritic cells (DC) and two human histocompatibility antigen (HLA-A2)-specific prostate-specific membrane antigen (PSMA) peptides, was recently completed. Thirty percent of the participa
Autor:
Gerald P. Murphy, S.J. Simmons, Abdel-Aziz A. Elgamal, Haakon Ragde, M.J. Troychak, Alton L. Boynton, Benjamin A. Tjoa, M. Rogers, G.M. Kenny
Publikováno v:
The Prostate. 39:291-297
BACKGROUND Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF; Leukine® [sargramostim], Immunex Corp., Seattle, WA) was administered to a subgroup of 44 patients in a phase II clinical trial for prostate cancer using DC pulse
Autor:
S.J. Simmons, Alton L. Boynton, Michael L Salgaller, M. Rogers, Gerald P. Murphy, Haakon Ragde, M.J. Troychak, G.M. Kenny, Benjamin A. Tjoa, Abdel-Aziz A. Elgamal
Publikováno v:
The Prostate. 39:54-59
BACKGROUND A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 and -P2). This report describes the evaluation of 37 subjects adm